DERMATOP Drug Patent Profile

Which patents cover Dermatop, and what generic alternatives are available?

Dermatop is a drug marketed by Valeant Pharms North and Valeant Bermuda and is included in two NDAs.

The generic ingredient in DERMATOP is prednicarbate. There are four drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the prednicarbate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Dermatop

A generic version of DERMATOP was approved as prednicarbate by FOUGERA PHARMS on March 9^th, 2007.

Summary for DERMATOP

US Patents:	0
Applicants:	2
NDAs:	2
Raw Ingredient (Bulk) Api Vendors:	44
Clinical Trials:	1
Patent Applications:	5,457
DailyMed Link:	DERMATOP at DailyMed

Recent Clinical Trials for DERMATOP

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Technische Universität Dresden	N/A

See all DERMATOP clinical trials

US Patents and Regulatory Information for DERMATOP

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Valeant Pharms North	DERMATOP	prednicarbate	OINTMENT;TOPICAL	019568-001	Sep 23, 1991		DISCN	Yes	No
Valeant Bermuda	DERMATOP E EMOLLIENT	prednicarbate	CREAM;TOPICAL	020279-001	Oct 29, 1993		DISCN	Yes	No

Expired US Patents for DERMATOP

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Valeant Pharms North	DERMATOP	prednicarbate	OINTMENT;TOPICAL	019568-001	Sep 23, 1991	4,242,334

International Patents for DERMATOP

See the table below for patents covering DERMATOP around the world.

Country	Patent Number	Title	Estimated Expiration
Hungary	182732	PROCESS FOR PRODUCING CORTICOID-17-ALKYL CARBONATES
Spain	472147
Australia	522854
Japan	H0112758
Canada	1118411	CORTICOIDE 17-(ALKYL CARBONATES), ET METHODES DE PREPARATION (CORTICOID 17-(ALKYL CARBONATES) AND PROCESSES FOR THEIR PREPARATION)
Austria	372093

DERMATOP Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for Atopic Dermatitis Drugs, Including DERMATOP

Introduction to Atopic Dermatitis Drugs Market

Atopic dermatitis, also known as eczema, is a chronic skin condition characterized by inflammation, itching, and dryness. The market for atopic dermatitis drugs is experiencing significant growth, driven by increasing disease prevalence, advancements in drug development, and changing lifestyle and environmental factors.

Global Market Size and Growth

The global atopic dermatitis drug market was valued at USD 13.62 billion in 2023 and is estimated to reach around USD 31.44 billion by 2034, growing at a CAGR of 7.9% from 2024 to 2034[1].

Regional Market Dynamics

North America holds the largest revenue share, accounting for 36% of the market in 2023. The U.S. atopic dermatitis drug market alone was valued at USD 3.44 billion in 2023 and is expected to reach around USD 8.10 billion by 2034, growing at a CAGR of 8.1% from 2023 to 2032[1].

Drug Class and Market Segmentation

The market is segmented by drug class, including biologics, calcineurin inhibitors, PDE-4 inhibitors, corticosteroids, and others. Biologics have emerged as a dominant segment, with drugs like Dupixent (dupilumab/Sanofi Regeneron) and Opzelura (ruxolitinib) cream 1.5% (Incyte) leading the market. These biologics accounted for 76% of the global market in 2021[4].

Role of DERMATOP in the Market

DERMATOP, a topical corticosteroid, is part of the broader corticosteroids segment. While specific financial data for DERMATOP is not provided, it is included in the portfolio of anti-inflammatory drugs acquired by Fidia Farmaceutici from Sanofi. This acquisition highlights the strategic importance of such drugs in the therapeutic landscape.

Acquisition and Market Impact

Fidia Farmaceutici's acquisition of a portfolio of anti-inflammatory drugs, including DERMATOP, from Sanofi, underscores the company's commitment to expanding its presence in the pharmaceutical market. This move is part of Fidia's growth strategy, focusing on consolidation and entering new therapeutic areas despite global health challenges[5].

Distribution Channels and Accessibility

Retail pharmacies play a significant role in the market growth, offering more accessibility, convenience, and prescription dispensing. The escalating popularity of telemedicine and online pharmacies also enhances access to these drugs, contributing to the overall market expansion[4].

Regulatory and Reimbursement Environment

Favorable reimbursement policies are expected to fuel the market prospects in the near future. Regulatory approvals for new biologics and other innovative treatments further support the growth of the atopic dermatitis drugs market[4].

Technological Advancements and Personalized Medicine

The market is driven by groundbreaking innovations, including the development of novel treatments and personalized medicine approaches. Compounded topical drugs, for instance, are gaining traction due to their ability to cater to individual patient needs, supported by advancements in compounding technologies and formulations[3].

Increasing Disease Prevalence and Global Awareness

The rising prevalence of dermatological conditions, including atopic dermatitis, and increasing global awareness of skin health are key drivers of the market. Over 150 new dermatology drugs are in development stages, indicating a robust pipeline that will continue to fuel market growth[2].

Market Challenges and Opportunities

Despite the growth, the market faces challenges such as regulatory hurdles and the need for continuous innovation. However, these challenges also present opportunities for companies to differentiate themselves through strategic collaborations, acquisitions, and investments in research and development.

Financial Trajectory for Atopic Dermatitis Drugs

The financial trajectory for atopic dermatitis drugs, including those like DERMATOP, is positive. Here are some key financial insights:

• Global Market Size: Expected to reach USD 31.44 billion by 2034[1].
• U.S. Market Size: Expected to reach around USD 8.10 billion by 2034[1].
• CAGR: 7.9% globally and 8.1% in the U.S. from 2023 to 2032[1].

Key Takeaways

• The global atopic dermatitis drugs market is growing significantly, driven by increasing disease prevalence and advancements in drug development.
• Biologics dominate the market, with a strong pipeline of new treatments.
• Distribution channels, including retail and online pharmacies, enhance accessibility.
• Favorable reimbursement policies and regulatory approvals support market growth.
• Personalized medicine and compounded topical drugs are gaining traction.
• Strategic acquisitions and collaborations are key to market expansion.

FAQs

1. What is the projected global market size for atopic dermatitis drugs by 2034? The global atopic dermatitis drug market is expected to reach around USD 31.44 billion by 2034[1].

2. Which region holds the largest revenue share in the atopic dermatitis drugs market? North America holds the largest revenue share, accounting for 36% of the market in 2023[1].

3. What is the role of biologics in the atopic dermatitis drugs market? Biologics are the dominant segment, accounting for 76% of the global market in 2021, with drugs like Dupixent and Opzelura leading the market[4].

4. How does the acquisition of anti-inflammatory drugs by Fidia Farmaceutici impact the market? The acquisition strengthens Fidia's position in the pharmaceutical market, particularly in the therapeutic areas of anti-inflammatory drugs, and supports the company's international growth strategy[5].

5. What are the key drivers of the atopic dermatitis drugs market? Key drivers include increasing disease prevalence, advancements in drug development, favorable reimbursement policies, and the rising global awareness of skin health[1][2][4].

Cited Sources:

1. Precedence Research - Atopic Dermatitis Drugs Market Size to Hit USD 31.44 Bn By 2034
2. GlobeNewswire - Global Dermatology Drugs Market to Worth Over US$ 50.42 Billion By 2032
3. Future Market Insights - Compounded Topical Drugs Market Sees Significant Growth
4. Managed Healthcare Executive - The Booming Market for Atopic Dermatitis Drugs
5. PR Newswire - Fidia Farmaceutici Continues On Its Growth Path